Citations

Clear

784 citation(s) found for "Leonard, L M".

TDP-43–Associated Neurodegenerative Disease Conceptualization and Integrated Staging
Benatar, Michael, Lagier‐Tourenne, Clotilde , Gregory, Jenna, Al-Chalabi, Ammar, Boeve, Bradley F., Maragakis, Nicholas J., Wuu, Joanne, Zeier, Zane, Onyike, Chiadi, Lewcock, Joe, Hovinga, Collin, Jafar-nejad, Paymaan, Uspenskaya, Olga, Simmons, Adam, Browne, Susan E., Rohrer, Jonathan, Petrucelli, Leonard, Shapiro, Jacquelyn, Scharper, Deb, Boxer, Adam, Staffaroni, Adam M. , Dacks, Penny, Dave, Kuldip D. , Majo, Martina de, Mitic, Laura, Fradette, Stephanie , Haeberlein, Samantha Budd , Simuni, Tanya, Dunn, Billy, Lee, Edward B., Js, Gregory , Benatar, Michael, Barmada, Sami, Jicha, Gregory A. , Al‐Chalabi, Ammar , Boeve, Bradley F. , Jack, Clifford R. , Seeley, William W. , Maragakis, Nicholas J. , Wuu, Joanne , Zeier, Zane R. , Hovinga, Collin A. , Jafar‐Nejad, Paymaan , Uspenskaya, Olga, Simmons, Adam, Browne, Susan E. , Petrucelli, L, Ostrow, Lyle W. , Dacks, Penny A. , Turner, Martin R. , Majo, Martina de , Simuni, Tanya , McMillan, Corey T. , Lee, Edward B.

Mayo Clinic

JAMA Neurology | August 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamaneurol.2026.2812 | PMID 42636000 Get It

Importance Classifying disease based on underlying pathobiology rather than clinical phenotype has implications for the development of biomarkers and therapy development. Observations Transactive response DNA-binding protein 43 kDa (TDP-43) pathology is observed across a range of clinically defined neurodegenerative disorders including limbic predominant age-related encephalopathy (LATE), most cases of amyotrophic lateral sclerosis (ALS), inclusion body myositis, multisystem proteinopathy, and approximately half the cases of frontotemporal dementia (FTD). Despite this shared biology, the current nosology for these neurodegenerative disorders is based on their distinct clinical phenotypes. An alternative approach recognizes the central role of TDP-43 pathology in disease pathogenesis, reserving the use of clinical terms like ALS, FTD, or LATE to describe phenotypic manifestations of underlying pathobiology. This approach also recognizes the converging biomarker and neuropathological data indicating that pathology begins presymptomatically, before the overt clinical manifestations of disease appear. Conclusions and Relevance In proposing a pathobiological definition of disease, the goal is to provide a road map for developing biomarkers that accurately reflect the underlying pathobiology of disease and for advancing therapeutic candidates that effectively target fundamental disease mechanisms.
Reproducibility of overall survival in metastatic colorectal cancer randomized trials using ARCAD-Derived external control arms
Raeisi, Morteza, André, Thierry, Shi, Qian, Yoshino, Takayuki, Adams, Richard, Cremolini, Chiara, Meyerhardt, Jeffrey A, Tie, Jeanne, Cohen, Romain, Bachet, Jean‐Baptiste , Bando, Hideaki, Misumi, Toshihiro, Bokemeyer, Carsten, Koopman, Miriam, Heinemann, Volker, Peeters, Marc, Cutsem, Eric Van, Grothey, Axel, Gramont, Aimery de, André, Thierry , Shi, Qian , Yoshino, Takayuki , Raeisi, Morteza , Bando, Hideaki , André, Thierry , Shi, Qian , Yoshino, Takayuki , Bando, Hideaki , Adams, Richard , Cremolini, Chiara , Meyerhardt, Jeffrey A. , Tie, Jeanne , Cohen, Romain , Misumi, Toshihiro , Bokemeyer, Carsten, Saltz, Leonard B. , Koopman, Miriam , Heinemann, Volker , Cutsem, Eric Van , Grothey, Axel , Chibaudel, Benoist , Gramont, Aimery de

Mayo Clinic

JNCI: Journal of the National Cancer Institute | August 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jnci/djag291 | PMID 42633557 Get It

Abstract Background Synthetic control arms (SCAs) derived from historical trial data can complement randomized controlled trials (RCTs), particularly in oncology where feasibility, ethical, and cost constraints may limit conventional trial designs. However, their validity for overall survival (OS) remains uncertain. We evaluated the feasibility and limitations of constructing SCAs from the ARCAD metastatic colorectal cancer (mCRC) database across multiple treatment lines. Methods Seven landmark RCTs representing first-, second-, and third-line settings were selected. External control arms were constructed from ARCAD individual patient-level data using propensity score matching based on key clinical and biological variables from a validated ARCAD prognostic score, with adjustment for geographic region and time era when needed. A prespecified two-step benchmarking framework assessed: (1) control-arm OS reproducibility and (2) virtual trial comparisons between matched synthetic controls and original RCT experimental arms. Agreement was evaluated using hazard ratios (HRs) and Z-tests. Results A total of 28,022 patients met the inclusion criteria. ARCAD-derived SCAs were successfully constructed for all selected RCTs and closely reproduced control-arm OS. After matching, baseline characteristics were well balanced, with minimal differences between included and excluded patients. Virtual trials showed concordant treatment-effect estimates with the original RCTs, with a median absolute HR deviation of 0.05 and no significant differences by Z-tests (P>.05). Survival outcomes were consistently reproduced across treatment lines. Conclusion ARCAD-derived SCAs reliably reproduced control-arm OS and benchmark treatment-effect estimates from landmark RCTs in mCRC. Despite limitations related to residual confounding and missing data, this framework supports benchmarking, trial design, and exploratory analyses when conventional control arms are impractical.
Oral administration of dibenzoylmethane (DBM) prevents cognitive decline in a C9ORF72-mediated FTD mouse model
Torres, Paulina, Becerra, Daniela, Astorga, José I., Kauwe, Grant, Gonzalez, Luis, Diaz, Guillermo, Morales, Vania, Valenzuela, Vicente, Wehrfritz, Cameron, Ngwala, Yani Y., Sepúlveda-Quiñenao, Claudia, Shah, Samah , Petrucelli, Leonard , Hetz, Claudio , Torres, Paulina , Fuentealba, Matías , Bons, Joanna , Tracy, Tara E. , Schilling, Birgit , Hetz, Claudio , Petrucelli, Leonard

Mayo Clinic

No container title available | August 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.08.07.743573 | PMID 42845299 Get It

Abstract Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are two related neurodegenerative disorders that display overlapping features. The hexanucleotide repeat expansion GGGGCC (G 4 C 2 ) in the C9ORF72 gene is the most common cause of ALS and FTD, which results in the accumulation of dipeptide-repeat protein aggregates. Regulation of protein synthesis at the level of the initiation factor eIF2α has been suggested as a transversal event contributing to neurodegeneration in ALS and FTD. eIF2α phosphorylation blocks protein synthesis to alleviate protein misfolding overload, but conversely it can reduce the expression of synaptic proteins resulting in neuronal dysfunction. Dibenzoylmethane (DBM) is a small molecule that reverses the translational attenuation mediated by eIF2α phosphorylation which has been shown to alleviate neurodegeneration in prion-infected mice and Tau transgenic animals. Here we investigated the efficacy of the oral administration of DBM in protecting a mouse model of C9ORF72 pathogenesis. Treatment of mice with 0.5% of DBM mixture in powdered food ad libitum was sufficient to prevent cognitive impairment in C9ORF72 mice. Unexpectedly, DBM treatment did not modify the content of poly(GA) and poly(GR) protein inclusion in the hippocampus and brain cortex. Proteomic profiling of brain tissue indicated that DBM administration corrected nearly 70% of the changes in gene expression triggered by expanded G 4 C 2 , where the main pathways modified by DBM were related to cytoskeleton organization, ALS, and metabolic processes. Most proteins corrected by DBM in our C9ORF72 model were also altered in the brain of human FTD/ALS patients. Overall, our results reinforce the idea that targeting protein synthesis with small molecules in patients carrying C9ORF72 mutations may result in improved cognitive capacity.
Progranulin deficiency perturbs lipid metabolism in white matter microglia
Yu, Dahyun , Armour, Ellen, Davis, Sonnet, Suh, Jung Do , Simon, Matthew, Tong, Jimei, Paolo, Gilbert Di , Petrucelli, Leonard , Davis, Sonnet S. , Suh, Jung, Simon, Matthew J.

Mayo Clinic

No container title available | July 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.07.27.740601 | PMID 42619690 Get It

Progranulin (PGRN) deficiency is a common hallmark in frontotemporal dementia (FTD) patients with granulin ( GRN ) mutations (FTD- GRN ). Previous studies by our group and others have observed that reduced PGRN perturbs lysosomal function and microglial activation, which is believed to accelerate neurodegeneration in FTD- GRN patients. Lysosomal function is intrinsically linked to lipid metabolism, and evidence suggests that GRN deficiency can alter lipid profiles in the brain. Unfortunately, studies to date have focused on whole brain or cortical extracts, limiting our ability to assess cell type-dependent changes in lipid metabolism under disease conditions. Here, we employed lipidomic analysis specifically within the pontine microglia of Grn knock-out (KO) mice, a cell population that was previously linked to disease phenotypes in this model. We observed a significant reduction in the endolysosomal lipid bis(monoacylglycero)phosphate (BMP) and the lipid metabolite phosphatidylethanolamine (PE); these microglial-specific lipid alterations mirror previous whole-brain findings, suggesting that similar changes may occur across multiple cell types in the brain. We also detected a significant increase in the myelin-composing factor galactosylceramide (GalCer), which may reflect an aberrant accumulation of myelin debris within microglia that arises due to defective lysosomal clearance. Notably, lipid perturbations were exacerbated with age within Grn KO microglia, suggesting that changes in lipid metabolism are both age- and genotype-dependent in this model. Together, our results support our hypothesis that PGRN acts as a master regulator of critical microglial processes – including lysosomal function, lipid metabolism, and the regulation of myelination – in an age-dependent manner.
The Chauvet 2025 meeting report: an update on current psychosocial research in vascularized composite allotransplantation
Stark, Helen, Talbot, Simon, Leonard, David, Rohovyy, Vasyly, Morelon, Emmanuel, Petruzzo, Palmina, Bellew, Maggie , Kumnig, Martin, Jowsey-Gregoire, Sheila G, Stark, Helen L. , Jowsey‐Gregoire, Sheila G. , Talbot, Simon , Lassus, Patrik , Amer, Hatem , Morélon, Emmanuel , Petruzzo, Palmina

Mayo Clinic

Frontiers in Transplantation | July 22, 2026 | Volume: 5 | Issue: No issue available | Pages: No page available

10.3389/frtra.2026.1900898 | PMID 42558802 Get It

Under the auspices of the International Society of Vascularized Composite Allotransplantation (ISVCA), a section of the Transplantation Society (TTS) that promotes and encourages research and training in the field of vascularized composite allotransplantation (VCA), the 4th Chauvet Workshop was convened in conjunction with the biennial meeting of the ISVCA from 27–29th June 2025 in Helsinki, Finland. The Chauvet workgroup recognizes the importance of psychological evaluation and management in VCA and works to provide an interdisciplinary platform for the development of psychosocial guidelines for the field. For the first time this workshop was conducted jointly with the ISVCA biennial congress, facilitating wider attendance, and discussions between different units and across disciplines. Three main areas were discussed; outcomes and lessons learned, qualitative research approaches and patient reported outcome measures (PROMS), and the role of team science in complex care models. We also heard an update from patient advocate Vasyly Rohovyy, on the progress being made to develop a VCA patient support and advocacy community. Here we summarize these discussions.
Plasma Phosphorylated Tau 217 in Participants at Risk for Chronic Traumatic Encephalopathy
Miner, A, Zetterberg, Henrik, Blennow, Kaj, Groh, Jenna R., Singh, Alpana, Dieckhoff, Kari, Tripodis, Yorghos, Adler, Charles H., Balcer, Laura J. , Bernick, C L, Peskind, Elaine, Asken, Breton M., Tanner, Jeremy A., Rabinovici, Gil D., Banks, Sarah J., Barr, William B., Wethe, Jennifer V., Cantu, Robert C., Dodick, David W., Mez, Jesse, Palmisano, J, Martin, Brett, Stein, Thor D., McKee, Ann C., Cummings, Jeffrey L., Shenton, Martha E., Reiman, E Bieto, Rc, Stern, Ashton, Nicholas J., Alosco, Michael L., Chen, Kewei, Protas, Hillary, Su, Yi, Boker, Connie, Au, Rhoda, Farrer, Lindsay, Helm, Robert, Kowall, Neil, Mercier, Gustavo, Otis, James, Weller, Jason, Bragg, Tahlia, Simkin, Irene, Trujillo-Rodriguez, Diana, Amerongen, Suzan van , Andino, Alondra, Conneely, Shannon, Diamond, Courtney, Fagle, Tessa, Haller, Olivia, Hunt, Tennyson, Gullotti, Nicole, Kossow, Bailey, Kugelmass, Carrie, Mariani, Megan, Mayville, Brian, McLaughlin, Kathleen, Nanna, Mary, DiPopolo, Marty, Platt, Taylor, Rice, Fiona, Sestak, Madison, McClean, Michael, Annis, Douglas, Chaisson, Christine, Dixon, Diane, Finney, Carolyn, Gallagher, Kerrin, Hartlage, Kaitlin , Lu, Jun, Ojo, E O, Pine, Brittany, Ramachandran, Janani, Baucom, Zachary, Tuz‐Zahra, Fatima , Yhang, Eukyung , Bouix, Sylvain, Fitzsimmons, Jennifer, Lin, Alexander P., Koerte, Inga K., Pasternak, Ofer, Arciniega, Hector , Billah, Tashrif , Bonke, Elena, Breedlove, Katherine M. , Carrington, Holly, Coello, Eduardo , Coleman, Michael J., John, Omar , Jung, Leonard, Liao, Huijun, Loy, Maria, Rizzoni, Elizabeth, Schulz, V. D., Silva, Annelise, Vessey, Brynn, Wiegand, Tim L.T, Miller, Jason, Ritter, Aaron , Sabbagh, Marwan, Cruz, Raelynn de la, Durant, Jan, Golceker, Morgan, Harmon, Nicolette, Kaylegian, Jaeson, Long, Rachelle, Nance, Christine, Sandoval, Priscilla, Staples, Miranda, Clark, Emma F., Serrano, Andrew, Geda, Yonas, Duffy, Amy, Falk, Bryce, Howard, Marci, Montague, Michelle , Osgood, Thomas, Babcock, Debra, Bellgowan, Patrick, GOLDBERG, JUDITH, Joseph, Binu , Kirov, Ivan, Lui, Yvonne, Marmar, Charles, Wisniewski, T R, Al-Kharafi, Alhassan, George, Allan, Hasanaj, Lisena, Martin, Sammie, Riley, Edward, Runge, William, Serrano, Liliana , Iliff, Jeffrey, Li, Gail, Janssen, D, Meabon, James, Piantino, Juan, Schindler, Abigail, Thomas, Ronald, Colasurdo, Elizabeth , Shofer, Jane, Marcus, Daniel S., Gurney, Jenny , Greenwald, Richard, Johnson, Keith A., Singh, Alpana , Singh, Alpana , Miner, Annalise E., Zetterberg, Henrik , Blennow, Kaj , Groh, Jenna R. , Singh, Alpana, Tripodis, Yorghos , Adler, Charles H. , Bernick, Charles , Peskind, Elaine R. , Asken, Breton M. , Rabinovici, Gil D. , Banks, Sarah J. , Barr, William , Wethe, Jennifer V. , Cantu, Robert C. , Dodick, David W. , Mez, Jesse , Stein, Thor D. , McKee, Ann C. , Cummings, Jeffrey L. , Shenton, Martha E. , Reiman, Eric M. , Ashton, Nicholas J. , Alosco, Michael L. , Protas, Hillary , Au, Rhoda, Weller, Jason , Trujillo‐Rodriguez, Diana , Fagle, Tessa, Mariani, Megan, McLaughlin, Kathleen , Pulukuri, Surya Vamsi , Sestak, Madison, McClean, Michael D , Annis, Douglas, Finney, Carolyn, Lu, Jun, Pine, Brittany, Ramachandran, Janani , Baucom, Zachary, Bouix, Sylvain , Koerte, Inga K , Pasternak, Ofer , Bonke, Elena M. , Carrington, Holly , Coleman, Michael J. , Liao, Huijun, Schulz, Vivian, Wiegand, Tim L. T. , II, Robert W. Turner , Marek, Kenneth , Geda, Yonas E. , Howard, Marci, Montague, Michelle, Babcock, Debra, Bellgowan, Patrick S.F. , Kirov, Ivan, George, Allan, Meabon, James S. , Piantino, Juan , Thomas, Ronald G. , Colasurdo, Elizabeth A. , Shofer, Jane, Marcus, Daniel S., Johnson, Keith A.

Mayo Clinic

JAMA Network Open | July 13, 2026 | Volume: 9 | Issue: 7 | Pages: e2622966

10.1001/jamanetworkopen.2026.22966 | PMID 42440317 Get It

Importance In vivo biomarkers for detecting neuropathologies from repetitive head impacts (RHI), including chronic traumatic encephalopathy (CTE), are needed. Objective To evaluate the utility of plasma phosphorylated tau 217 (p-tau217), assess its performance as a beta-amyloid (Aβ) biomarker in participants with RHI exposure at risk for CTE, and explore concordance with CTE neuropathology in a postmortem subsample. Design, Setting, and Participants This longitudinal, multicenter, case-control study used data from the Diagnostics, Imaging, and Genetics Network for the Objective Study and Evaluation of CTE (DIAGNOSE CTE) Research Project, collected from September 2016 to October 2023. Participants were former American football players (case participants) and asymptomatic men unexposed to RHI (control participants). A subsample had available neuropathologic data. Exposures RHI, traumatic encephalopathy syndrome (TES) diagnoses, and levels of CTE certainty. Main Outcomes and Measures Plasma p-tau217 (classified as positive [≥0.63 pg/mL], intermediate [0.40-0.62 pg/mL], and negative [<0.40 pg/mL]), Aβ–positron emission tomography (PET; 18 F-florbetapir; with Aβ-positive defined as a standardized uptake value ratio [SUVR] ≥1.10), and tau-PET ( 18 F-flortaucipir). TES diagnoses were assigned by multidisciplinary consensus conference. Analyses of postmortem brains controlled for age, race, and APOE ε4 status. Results Among 231 participants (mean [SD] age, 57.75 [8.25] years), 177 were former football players (117 professional and 60 college) and 54 were unexposed participants. Former football players had higher baseline mean (SD) p-tau217 concentrations than unexposed participants (0.35 [0.26] pg/mL vs 0.27 [0.14] pg/mL; P = .008), although this was driven by a higher proportion of Aβ-PET–positive participants among former players. Plasma p-tau217 increased over time across the sample (B = 0.207 [95% CI, 0.117-0.298]; P < .001), with no significant time × exposure group interactions. Among football players, p-tau217 showed no time × group interactions with TES diagnosis, TES-CTE certainty, or RHI metrics. Higher p-tau217 concentration correlated with higher global Aβ-PET SUVR (B = 0.058 [95% CI, 0.053-3.501; P = .01), with a few discordant cases (5 participants were p-tau217–negative and Aβ-PET–positive; 7 participants were p-tau217–positive and Aβ-PET–negative). P-tau217 had similar areas under the curve for projecting Aβ-PET positivity as cerebrospinal fluid (CSF) p-tau181/Aβ42 and CSF Aβ40/42 measures (p-tau217: AUC, 0.88 [95% CI, 0.80-0.96]; CSF p-tau181/Aβ42: AUC, 0.89 [95% CI, 0.79-1.00]; CSF Aβ40/42: AUC, 0.85 [95% CI, 0.72-0.98]). Among 9 brain donors, 6 had CTE (stages II-IV; none with Alzheimer disease). Seven had negative or intermediate p-tau217, concordant with Aβ-PET. Two p-tau217 outliers with stage III CTE had normal concentrations upon additional testing. Conclusions and Relevance The findings of this study suggest that plasma p-tau217 concentration is unlikely to be useful for the detection of CTE, but it does show utility for ruling out Aβ pathology in participants at risk for CTE.
TDP-43 subtypes shape transcriptomic signatures in Alzheimer’s disease
Wang, Xiaojie, Reeves, Madison M, Bejarano, Jesús González , Song, Yuping , Dunmore, Judy, Yue, Mei, Rawlinson, Bailey, DeTure, Michael, Tome, Raul Baena, Narayan, Anand, Bartfield, Jordan, Graff‐Radford, Neill R. , Peterson, Ronald C. , Oskarsson, Björn, Murray, Melissa E, Dickson, DW, Cook, Casey, Zhang, Yongjie, Petrucelli, Leonard , Josephs, Keith A, Walker, Alyssa C. , Reeves, Madison M., Dunmore, Judy H., Yue, Mei, Rawlinson, Bailey, Engelberg-Cook, Erica , DeTure, Michael , Narayan, Anand, Boeve, Bradley F. , Knopman, David S. , Day, Gregory S. , Murray, Melissa E. , Dickson, Dennis W. , Josephs, Keith A. , Prudencio, Mercedes

Mayo Clinic

No container title available | June 26, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.22.733827 | PMID 42395416 Get It

Abstract TAR DNA-binding protein 43 (TDP-43) pathology frequently co-occurs with Tau neurofibrillary tangles (NFTs) and amyloid β plaques in Alzheimer’s disease (AD), driving significant clinical heterogeneity. Whether TDP-43 engages autonomous molecular programs or instead amplifies Tau-driven neurodegeneration remains difficult to resolve, largely because these pathologies often co-occur. To separate these overlapping signatures, we generated regionally resolved transcriptomic profiles from cognitively normal controls (Controls), neuropathologically defined cohorts of AD, AD with limbic-predominant age-related TDP-43 encephalopathy (AD/LATE), and frontotemporal lobar degeneration (FTLD-TDP), categorizing them by their distinct TDP-43 subtypes (types α and β for AD/LATE; types A and B for FTLD-TDP). By integrating transcriptomic profiles with quantitative measures of phosphorylated TDP-43 (pTDP-43) and Tau (pTau), we separated pathology-associated signals within mixed disease contexts. We found that TDP-43 is linked to distinct transcriptomic programs in AD/LATE that are largely uncoupled from Tau burden and diverge from those observed in FTLD-TDP. These signatures showed regional specificity, with transcriptomic remodeling occurring in the amygdala across both diseases, whereas frontal cortex alterations were largely restricted to FTLD-TDP. Furthermore, by stratifying cases by TDP-43 morphological subtype, we unmasked specific biological trajectories, from immune activation to unique cellular vulnerabilities, that are not apparent in unstratified cohorts. Together, our findings provide a framework for decoupling mixed proteinopathies and demonstrate that TDP-43 shapes autonomous, subtype-dependent transcriptional landscapes in AD.
Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL
Othman, Tamer , Roloff, Gregory W. , Miller, Katharine, Zhang, Amy , Sutherland, Katherine C. , Faramand, Rawan , Hill, LaQuisa C. , Jeyakumar, Nikeshan , Ladha, Abdullah , Kopmar, Noam E., Tsai, Stephanie B., O'CONNOR, TIMOTHY E., Solh, Melhem , Guzowski, Caitlin, Tan, Virginia, Malik, Shahbaz A., Mathews, John, Shaughnessy, Paul , Mountjoy, Luke, Schwartz, Marc S., Connor, Matthew P. , Vasu, Sumithira, Kumaran, Muthu, Hoeg, Rasmus T., Tracy, Sean , Yaghmour, George , Pullarkat, Vinod , Muffly, Lori , Aldoss, Ibrahim, Jeyakumar, Nikeshan , Ladha, Abdullah , Sasine, Joshua , Lin, Chenyu , Hilal, Talal , Majhail, Navneet S , Dykes, Kaitlyn C , Logan, Aaron C , Connor, Matthew , Cassaday, Ryan D , Leonard, Jessica T , Shah, Bijal , Frey, Noelle V , Muffly, Lori , Hill, LaQuisa C , Faramand, Rawan , Sutherland, Katherine , Roloff, Gregory W , Othman, Tamer , Zhang, Amy , Muhsen, Ibrahim N. , Sasine, Joshua , Lin, Chenyu , Kopmar, Noam E. , Tsai, Stephanie, Hilal, Talal , Majhail, Navneet S. , Battiwalla, Minoo , Malik, Shahbaz A. , Mountjoy, Luke , Dykes, Kaitlyn C. , Wang, Jiasheng , Vasu, Sumithira , Hoeg, Rasmus T. , Yalniz, Fevzi , Cassaday, Ryan D. , Shah, Bijal , Frey, Noelle V. , Aldoss, Ibrahim

Mayo Clinic

Blood Advances | June 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2026020707 | PMID 42349018 Get It

Brexucabtagene-autoleucel (brexu-cel) produces high rates of measurable residual disease-negative (MRD-) complete response (CR) in adults with Philadelphia-chromosome positive (Ph+) acute lymphoblastic leukemia (ALL); however, subsequent relapses remain frequent. It is unclear whether maintenance with tyrosine kinase inhibitors (TKIs) can enhance remission durability. We evaluated outcomes among adults with relapsed/refractory Ph+ ALL who received commercial brexu-cel and achieved MRD- CR across 19 U.S. institutions. Considering TKI maintenance as a time-varying covariate, we analyzed outcomes based on receipt of subsequent TKI maintenance versus no maintenance. Patients receiving consolidative transplantation or non-TKI maintenance were excluded. Fifty-one patients were included: 20 received TKI maintenance and 31 received no maintenance. The use of TKI maintenance was associated with a significantly lower 1-year cumulative incidence of relapse (HR 0.12; 95% CI, 0.02-0.88; p=0.037) which translated into improved progression-free survival (PFS, HR 0.19; 95% CI, 0.04-0.85; p=0.029) and a trend towards improved overall survival (OS, HR 0.34; 95% CI, 0.07-1.62; p=0.18). There was no difference in non-relapse mortality (NRM, HR 0.83; 95% CI, 0.12-5.87; p=0.85). This real-world analysis supports the administration of TKI maintenance in Ph+ ALL following achievement of MRD- CR with brexu-cel as a strategy to improve PFS following chimeric antigen receptor T cell therapy.
ID #155 CONNECT TarGeT-H Phase 1/2 Clinical Study of a Novel Telomere-Targeting Therapy for Pediatric High-Grade Glioma (HGG) including Diffuse Intrinsic Pontine Glioma (DIPG) Harboring Telomerase Activation
Umaru, Banlanjo, Salloum, Ralph, Wright-Nadkarni, Mariah, Lazow, Margot, Weinbrecht-Acree, Joanna, Haskinson, Kristen, Palmer, Joshua, Thomas, Diana, Rodriguez, Diana, Geyer, Susan, Leonard, J., Mardis, Elaine, Fouladi, Maryam, Tanaka, Ryuma , Umaru, Banlanjo Abdulaziz , Wright-Nadkarni, Mariah , Lazow, Margot , Fouladi, Maryam , Drissi, Rachid

Mayo Clinic

Neuro-Oncology Pediatrics | June 24, 2026 | Volume: 2 | Issue: Supplement_1 | Pages: No page available

10.1093/neuped/wuag026.037 Get It

Abstract Pediatric high-grade gliomas (HGGs), including diffuse intrinsic pontine glioma (DIPG), are among the most aggressive childhood brain tumors, with five-year survival rates below 10%. Current treatment options are limited to radiation, highlighting the urgent need for novel therapies. Telomere maintenance via telomerase activation is a hallmark of cancer, enabling replicative immortality. Our prior studies demonstrate telomerase activity in 73% of HGGs and 47% of DIPG, implicating telomere biology as a critical therapeutic target. 6-thio-dG (THIO) is a first-in-class telomere-targeting agent that incorporates into telomeres of telomerase-positive cells, inducing telomere uncapping, genomic instability, and apoptosis. THIO crosses the blood–brain barrier and exhibits synergy with radiation in preclinical DIPG models. Telomere dysfunction is confirmed by telomere dysfunction-induced foci (TIFs), marked by colocalization of DNA damage response proteins (ATM S1981-P, γH2AX, 53BP1) at telomeres. Historical pediatric leukemia trials established THIO’s safety profile, and recent adult studies in non-small cell lung cancer demonstrated efficacy at lower doses. As part of the biologically-guided umbrella trial CONNECT TarGeT [NCT05839379], we are developing TarGeT-H, a phase 1/2 and surgical study to evaluate THIO combined with focal radiation in pediatric, adolescent, and young adult patients with newly diagnosed HGG or DIPG harboring telomerase activation, confirmed by hTERT mRNA expression—assessed via tumor submission, profiling, and rapid central screening through TarGeT-SCR. Specific aims include: (1) determining pharmacokinetics and safety to establish the recommended Phase 2 dose (RP2D); (2) estimating efficacy by progression-free survival (HGG) and overall survival (DIPG) compared to historical controls; and (3) assessing telomere dysfunction in resected HGG tumors via TIF analysis. Up to 90 patients will receive THIO intravenously during radiation and maintenance cycles for up to two years. By leveraging a selective telomere-targeting mechanism distinct from current therapies and demonstrating synergy with radiation, THIO represents a promising strategy to improve outcomes in devastating pediatric cancers.
Emerging directions in tauopathy research
Wildsmith, Kristin R., Alladi, Suvarna, Bertucci, Taylor, Bowles, Kathryn R. , Boxer, Adam, Brummet, Jennifer, DeVos, Sarah L., Diaz, Kristophe , Duff, Karen, Duran‐Aniotz, Claudia, Farrell, Kurt, Fontana, Igor C., Franzmeier, Nicolai, Frost, Bess, Petrucelli, Leonard, Rexach, Jessica, Reyderman, Larisa, Rommel, Amy, Bohórquez, Sandra M. Sanabria, Schöll, Michael, Schneider, Anja, Silva, Rohan de , Snyder, Heather M. , VandeVrede, Lawren, Varga, Andrew W, Vogel, Jacob W., Yeh, Felix L. , Yoo, Andrew S., Carrillo, Maria C., Duff, Karen , Bertucci, Taylor , Mahinrad, Simin , Buée, Luc , Alladi, Suvarna , Boche, Delphine , DeVos, Sarah L. , Dreyer, Anna J. , Duran‐Aniotz, Claudia , Durrant, Claire S. , Farrell, Kurt , Fontana, Igor C. , Franzmeier, Nicolai , Frost, Bess , Horie, Kanta , Kaňovský, Petr , Kao, Aimee W. , Mahinrad, Simin , Malpetti, Maura , Morris, Huw R. , Palleis, Carla , Petrucelli, Leonard , Rexach, Jessica E. , Reyderman, Larisa, Rowe, James B. , Bohórquez, Sandra Sanabria , Sato, Chihiro , Schneider, Anja , VandeVrede, Lawren , Varga, Andrew W. , Vogel, Jacob W. , Yoo, Andrew S.J. , Carrillo, María C.

Mayo Clinic

Alzheimer's & Dementia | June 22, 2026 | Volume: 22 | Issue: 6 | Pages: No page available

10.1002/alz.71431 | PMID 42324487 Get It

Abstract The Tau Global Conference 2025, hosted by the Alzheimer's Association, CurePSP, and the Rainwater Charitable Foundation, convened international experts from academia, industry, government, and philanthropy to explore advances and challenges in tauopathy research. The meeting highlighted progress across tau biology, including emerging models of tau regulation, degradation, and propagation; advances in biomarker development for the diagnosis and staging of tauopathies; and evolving therapeutic strategies targeting diverse aspects of tau pathophysiology. Discussions also emphasized the importance of cross‐sector collaboration, and global initiatives to address disparities in tau research. This report synthesizes key insights from the conference and underscores the critical role of interdisciplinary, biomarker‐driven, and globally inclusive approaches in accelerating the translation of tau research into effective clinical applications.